|
||||||||||||||||
| HUM-MOLGEN -> Events -> Meetings and Conferences | ||||||||||||||||
| Drug Discovery and Clinical Evaluation in the 21st Century | ||||||||||||||||
| June 21, 2001 | ||||||||||||||||
|
UT M. D. Anderson Cancer Center, JW Marriott Hotel, 5150 Westheimer, Houston, Texas January 16-18, 2002 WEDNESDAY A.M. - JANUARY 16, 2002 Welcome John Mendelsohn, M.D. President UT M. D. Anderson Cancer Center Keynote Speaker Drug Discovery, Development and Evaluation from NCI's Perspective Richard Klausner, M.D. National Cancer Institute Bethesda, Maryland SESSION I: IDENTIFICATION AND PRIORITIZATION OF NOVEL DRUG TARGETS Session Co-chairs: Gabriel Lopez-Berestein, M.D. and William K. Plunkett Jr., M.D. Apoptosis Stanley Korsmeyer, M.D. Dana-Farber Cancer Institute Boston, Massachusetts Cell Cycle William Kaelin, M.D. Dana-Farber Cancer Institute Boston, Massachusetts Kinases Carlos Arteaga, M.D. Vanderbilt University School of Medicine Nashville, Tennessee Signal Transduction Targets I Frank McCormick, M.D. University of San Francisco Cancer Center & Cancer Research Institute San Francisco, California Signal Transduction II Philip Needleman, Ph.D. Monsanto Corporation St. Louis, Missouri Angiogenesis/Metastasis Judah Folkman, M.D. Harvard Medical School Boston, Massachusetts Genomics/Proteomics Robert Tepper, M.D. Millennium Pharmaceuticals Cambridge, Massachusetts Discussion Kirt Matheson Aventis Mark Sliwkowski Genentech, Inc. South San Francisco, California Lunch WEDNESDAY P.M. - JANUARY 16, 2002 SESSION II: METHODS FOR PRECLINICAL EVALUATION AND PRIORITIZATION OF NOVEL DRUGS Session Co-chairs: Francis Ali-Osman, DSc and Stanley Hamilton, M.D. High Through Put Screening Raymond Budde, Ph.D. UT M. D. Anderson Cancer Center Houston, Texas Cell Lines John Weinstein, M.D. National Cancer Institute Bethesda, Maryland Clonogenic Assays John Fruehauff, M.D., Ph.D. Oncotech, Inc. Irvine, California Animal Models Beverly Teicher, Ph.D. Lilly Research Laboratories Indianapolis, Indiana Academic Perspective Daniel Von Hoff, M.D. Arizona Cancer Center Tucson, Arizona Industrial Perspective Ivan Horak, M.D. Pharmacia & Upjohn Peapack, New Jersey FDA Perspective Karen Weiss, M.D. Food and Drug Administration Rockville, Maryland Discussion Praveen Tyle, Ph.D. Pharmacia & Upjohn Kalamazoo, Michigan Louise Perkins, Ph.D. Bayer Corp. West Haven, CT Reception THURSDAY A.M. - JANUARY 17, 2002 Keynote Speaker Regulatory Processes in the Development and Evaluation of New Cancer Drugs Janet Woodcock, M.D. Food and Drug Administration Rockville, Maryland SESSION III: NOVEL CLINICAL TRIAL DESIGN AND IMPLEMENTATION Session Co-chairs: Gabriel Hortobagyi, M.D. and Elihu Estey, M.D. Trial Design I Richard Gelber, Ph.D. Dana-Farber Cancer Institute Boston, Massachusetts Trial Design II Donald Berry, Ph.D. UT M. D. Anderson Cancer Center Houston, Texas FDA Richard Pazdur, M.D. Food and Drug Administration Rockville, Maryland EORTC Martine Piccart-Gebhart, M.D., Ph.D. Jules Bordet Institute Brussels, Belgium US Trials Richard Schilsky, M.D. University of Chicago Chicago, Illinois Industry David Parkinson Novartis Pharmaceuticals Corporation East Hanover, New Jersey NCI Robert Wittes, M.D. National Cancer Institute Bethesda, Maryland Discussion Steven Averbush, M.D. Astra-Zeneca Wilmington, Delaware Perry Nisen Abbott Laboratories Abbott Park, IL Lunch THURSDAY P.M. - JANUARY 17, 2002 SESSION IV: CLINICAL TRIALS: ENDPOINTS AND PARTICIPANTS Session Co-chairs: Eugenie Kleinerman, M.D. and Michael Keating, M.D. Molecular Endpoints Gordon B. Mills, M.D., Ph.D. UT M. D. Anderson Cancer Center Houston, Texas Pharmacogenomics Robert Kramer, M.D. Bristol-Myers Squibb Princeton, New Jersey Diagnostic Imaging Donald Podoloff, M.D. UT M. D. Anderson Cancer Center Houston, Texas Supportive Care William Sheridan, MBBS Amgen, Inc. Thousand Oaks, California Pediatric Trials Gregory Reaman, M.D. Children's National Medical Center Washington, DC Adult Phase I-II Trials Hagop M. Kantarjian, M.D. UT M. D. Anderson Cancer Center Houston, Texas Geriatric Trials Hyman Muss, M.D. University of Vermont Burlington, Vermont Women & Minorities Edith Mitchell, M.D. Thomas Jefferson University Philadelphia, Pennsylvania Discussion Maryellen Ryback, M.D. Janssen Research Foundation Titusville, New Jersey David Luke, Pharm.D Pfizer Global Research and Development Groton, CT FRIDAY A.M. - JANUARY 18, 2002 Keynote Speaker Drug Discovery, Development and Evaluation in the 21st Century From Industry’s Perspective Steve Carter, M.D. Consultant New York, New York SESSION V: THE IMMEDIATE FUTURE OF MOLECULAR THERAPEUTICS Session Co-chairs: Waun Ki Hong, M.D. and Raphael E. Pollock, M.D., Ph.D. Tyrosine Kinase Inhibitors Moshe Talpaz, M.D. UT M. D. Anderson Cancer Center Houston, Texas Monoclonal Antibodies Louis Weiner, M.D. Fox Chase Cancer Center Philadelphia, Pennsylvania Farnesyl Transferase Inhibitors Allen Oliff, M.D. Dupont Pharmaceuticals Wilmington, Delaware Angiogenesis Inhibitors Roy Herbst, M.D., Ph.D. UT M. D. Anderson Cancer Center Houston, Texas Retinoids Richard Heyman, Ph.D. X-Ceptor Therapeutics San Diego, California Anti-Sense Ana Tari, Ph.D. UT M. D. Anderson Cancer Center Houston, Texas Gene Therapy Jack A. Roth, M.D. UT M. D. Anderson Cancer Center Houston, Texas Radiation Response Modifiers Norman Coleman, M.D. National Cancer Institute Bethesda, Maryland PRESENTATION OF THE HEATH MEMORIAL AWARD Vaccines Steven Rosenberg, M.D., Ph.D. National Cancer Institute Bethesda, Maryland |
||||||||||||||||
| Organized by: | UT M. D. Anderson Cancer Center | |||||||||||||||
| Invited Speakers: | Carlos Arteaga, M.D. Vanderbilt University School of Medicine Nashville, Tennessee Steven Averbush, M.D. Astra-Zeneca Wilmington, Delaware Donald Berry, Ph.D. UT M. D. Anderson Cancer Center Houston, Texas Raymond Budde, Ph.D. UT M. D. Anderson Cancer Center Houston, Texas Steve Carter, M.D. Consultant New York, New York Norman Coleman, M.D. National Cancer Institute Bethesda, Maryland Judah Folkman, M.D. Harvard Medical School Boston, Massachusetts John Fruehauff, M.D., Ph.D. Oncotech, Inc. Irvine, California Richard Gelber, Ph.D. Dana-Farber Cancer Institute Boston, Massachusetts Roy Herbst, M.D., Ph.D. UT M. D. Anderson Cancer Center Houston, Texas Richard Heyman, Ph.D. X-Ceptor Therapeutics San Diego, California Ivan Horak, M.D. Pharmacia & Upjohn Peapack, New Jersey William Kaelin, M.D. Dana-Farber Cancer Institute Boston, Massachusetts Hagop M. Kantarjian, M.D. UT M. D. Anderson Cancer Center Houston, Texas Richard Klausner, M.D. National Cancer Institute Bethesda, Maryland Stanley Korsmeyer, M.D. Dana-Farber Cancer Institute Boston, Massachusetts Robert Kramer, M.D. Bristol-Myers Squibb Princeton, New Jersey Gabriel Lopez-Berestein, M.D. UT M. D. Anderson Cancer Center Houston, Texas David Luke, Pharm.D Pfizer Global Research and Development Groton, CT Kirt Matheson Aventis Frank McCormick, M.D. University of San Francisco Cancer Center & Cancer Research Institute John Mendelsohn, M.D. UT M. D. Anderson Cancer Center Houston, Texas Gordon B. Mills, M.D., Ph.D. UT M. D. Anderson Cancer Center Houston, Texas Edith Mitchell, M.D. Thomas Jefferson University Philadelphia, Pennsylvania Hyman Muss, M.D. University of Vermont Burlington, Vermont Philip Needleman, Ph.D. Monsanto Corporation St. Louis, Missouri Perry Nisen Abbott Laboratories Abbott Park, IL Allen Oliff, M.D. Dupont Pharmaceuticals Wilmington, Delaware David Parkinson Novartis Pharmaceuticals Corporation East Hanover, New Jersey Richard Pazdur, M.D. Food and Drug Administration Rockville, Maryland Louise Perkins, Ph.D. Bayer Corp. West Haven, CT Martine Piccart-Gebhart, M.D., Ph.D. Jules Bordet Institute Brussels, Belgium William K. Plunkett Jr., M.D. UT M. D. Anderson Cancer Center Houston, Texas Donald Podoloff, M.D. UT M. D. Anderson Cancer Center Houston, Texas Gregory Reaman, M.D. Children’s National Medical Center Washington, DC Steven Rosenberg, M.D., Ph.D. National Cancer Institute Bethesda, Maryland Jack A. Roth, M.D. UT M. D. Anderson Cancer Center Houston, Texas Maryellen Ryback, M.D. Janssen Research Foundation Titusville, New Jersey Richard Schilsky, M.D. University of Chicago Chicago, Illinois William Sheridan, MBBS Amgen, Inc. Thousand Oaks, California Mark Sliwkowski Genentech, Inc. South San Francisco, California Moshe Talpaz, M.D. UT M. D. Anderson Cancer Center Houston, Texas Ana Tari, Ph.D. UT M. D. Anderson Cancer Center Houston, Texas Beverly Teicher, Ph.D. Lilly Research Laboratories Indianapolis, Indiana Robert Tepper, M.D. Millennium Pharmaceuticals Cambridge, Massachusetts Praveen Tyle, Ph.D. Pharmacia & Upjohn Kalamazoo, Michigan Daniel Von Hoff, M.D. Arizona Cancer Center Tucson, Arizona Louis Weiner, M.D. Fox Chase Cancer Center Philadelphia, Pennsylvania John Weinstein, M.D. National Cancer Institute Bethesda, Maryland Karen Weiss, M.D. Food and Drug Administration Rockville, Maryland Robert Wittes, M.D. National Cancer Institute Bethesda, Maryland Janet Woodcock, M.D. Food and Drug Administration Rockville, Maryland |
|||||||||||||||
| Deadline for Abstracts: | N/A | |||||||||||||||
| Registration: | On-site registration opens at 7:00 a.m. on Wesnesday, January 16, 2002, followed by the opening session at 8:00 a.m., and the conference will adjourn at 12:00 noon on Friday, January 18, 2002. Advance registration is encouraged as space and materials are limited. The deadline for advance registration is January 4, 2002. To pre-register, please go to the conference website and complete the on-line registration form. MasterCard, VISA, and American Express are accepted for on-line or Fax: 713-794-1724. If you are paying by check(payable through U.S. banks only) or money order to: 43rd Annual Clinical Conference, conference Services-HMB 131, UT M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030-4009. Registration Fee Schedule: The full conference registration fee includes the tuition, two lunches, breaks, and receptions. The student registration fee includes all of the above excluding lunches. Students wishing to participate in lunches, must pay an additional fee of $35.00. Postmarked: by 1/4/02 after 1/4/02 Full conference registration fee $375 $400 M. D. Anderson $250 $300 Associates Members Student registration fee $100 $125 Student lunch fee $35 $40 Students: A reduced registration fee has been established for full-time students and physicians in training (interns, residents, and fellows). All students claiming this reduced fee are required to submit a letter of introduction from the chairperson of their department with their registration form. |
|||||||||||||||
| E-mail: | meetings@mdaisd1.tmc.edu | |||||||||||||||
| Posted by: | Pam Hamre | |||||||||||||||
| Host: | conf100.mdacc.tmc.edu | |||||||||||||||
|
||||||||||||||||
|
Generated by meetings and positions 5.0 by Kai Garlipp |
||||||||||||||||